Skip to main content
. 2008 Aug;62(8):1159–1167. doi: 10.1111/j.1742-1241.2008.01820.x

Figure 6.

Figure 6

Patients’ preference of treatment efficacy according to study phase – relative frequencies by absolute naloxone prolonged-release (PR) dose (intention-to-treat population). In the placebo group, patients received oxycodone PR and a placebo. Whereas treatment groups received oxycodone PR plus naloxone PR 10, 20 or 40 mg/day